The outlook of companies tied to the drug's legacy presents a complex investment scenario . While the initial boom generated substantial gains, generic alternatives have significantly impacted revenue. Investing in associated pharmaceutical companies now requires a discerning assessment of intellectual property protection , evolving medical changes